Ovarian Cancer | Kathleen Moore, MD

The Evolving Role of PARP Inhibition in the Management of Ovarian Cancer — Faculty Presentation 3: Biologic Rationale for and Available Data with PARP Inhibition in Combination with Chemotherapeutic and Immunotherapeutic Agents in the Management of Advanced Ovarian Cancer — Dr Moore. CME information and select publications